Optimal use of maraviroc in clinical practice.
Soriano
Vincent
V
Geretti
Anna María
AM
Perno
Carlo-Federico
CF
Fätkenheuer
Gerd
G
Pillay
Deenan
D
Reynes
Jacques
J
Tambussi
Giuseppe
G
Calvez
Vincent
V
Alcamí
José
J
Rockstroh
Juergen
J
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D065100:CCR5 Receptor Antagonists; D018791:CD4 Lymphocyte Count / Q000379:methods; D003510:Cyclohexanes / Q000008:administration & dosage*; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D005260:Female; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage*; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D008297:Male; D000077592:Maraviroc; D019713:Receptors, CCR5 / Q000302:isolation & purification*; D014230:Triazoles / Q000008:administration & dosage*; D018523:Tropism / Q000502:physiology; D019562:Viral Load
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D019713:Receptors, CCR5; D014230:Triazoles; D000077592:Maraviroc